Chan Zhao

Dr. Chan Zhao

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
BWBingjie Wang
Bingjie Wang
XZXiao Zhang
Xiao Zhang
HCHuan Chen
Huan Chen
AKAdrian Koh
Adrian Koh
CZChan Zhao
Chan Zhao
YCYouxin Chen
Youxin Chen
Retinal vein occlusion (RVO) is one of the most common retinal vascular diseases. The pathogenesis of RVO is multifactorial and involves a complex interplay among a variety of vascular and inflammatory mediators. Many cytokines, chemokines, growth factors, and cell adhesion molecules have been reported to be implicated. Treatments for RVO are directed at the management of underlying risk factors and vision-threatening complications, including macula edema (ME) and neovascularization. Intravitreal anti-VEGF agents are currently considered as the first-line treatment for ME secondary to RVO (RVO-ME), but a substantial proportion of patients responded insufficiently to anti-VEGF agents. Since RVO-ME refractory to anti-VEGF agents generally responds to corticosteroids and its visual outcome is negatively correlated to disease duration, prediction of treatment response at baseline in RVO-ME may significantly improve both cost-effectiveness and visual prognosis. Several bioactive molecules in the aqueous humor were found to be associated with disease status in RVO. This review aims to present a comprehensive review of intraocular biomolecules reported in RVO, including VEGF, IL-6, IL-8, MCP-1, sICAM-1, IL-12, IL-13, sVEGFR-1, sVEGFR-2, PDGF-AA, etc., highlighting their association with disease severity and/or phenotype, and their potential roles in prognostic prediction and treatment selection. Some of these molecules may serve as biomarkers for aqueous humor-based companion diagnostics for the treatment of RVO in the future.

3 July 2021 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Open access
ALAnyi Liang
Anyi Liang
SJShanshan Jia
Shanshan Jia
FGFei Gao
Fei Gao
XHXiaoxu Han
Xiaoxu Han
MPMinghang Pei
Minghang Pei
MZMeifen Zhang
Meifen Zhang
Purpose: Changes of choroidal circulation throughout the disease course of Vogt-Koyanagi-Harada (VKH) disease and the clinical significance remain unclear. Choriocapillary vascular density (CC VD) measured by optical coherence tomography angiography (OCTA) were compared in different disease stages of VKH and its correlation with other parameters was analyzed, aiming to explore their clinical relevance. Methods: This is a retrospective case series. One hundred and fourteen VKH patients and 47 normal controls (NCs) were included. Patients were grouped into the acute uveitic, convalescent, and chronic recurrent stages (only anterior recurrent cases included), and OCTA images were obtained from VKH patients in these stages. Best corrected visual acuity (BCVA), CC VD, and subfoveal choroidal thickness (SFCT) were recorded and compared. Results: CC VD in acute (58.26% ± 0.84%), convalescent (64.85% ± 0.33%), and chronic recurrent (62.78% ± 0.70%) stage of VKH patients were all significantly lower than that in NCs (66.37% ± 0.41%) (p < 0.001, p = 0.017, and p < 0.001, respectively). CC VD increased by 6.59% ± 0.91% with resolution of acute inflammation (p < 0.001) and decreased by 2.07% ± 0.74% during anterior uveitis relapse (p = 0.009). Patients with a positive history of anterior recurrence had lower CC VD (− 2.43% ± 0.75%, p = 0.003) in the convalescent stage than those without. CC VD was negatively correlated with logMAR BCVA in VKH (r = − 0.261, p < 0.001). Conclusion: CC VD was decreased in every stage of VKH. CC VD has the potential to reflect the status of uveitis and might be promising in monitoring the disease activity. OCTA is a convenient and straightforward tool to evaluate choroidal vascularity, and CC VD provides supplemental quantitative information of the choriocapillaris. Further studies are needed to explore the values of OCTA quantitative parameters in monitoring VKH progression, predicting visual prognosis, and guiding clinical decisions.

19 June 2020 in PeerJ
Verified
Journal Article
Open access
PDF file
ALAnyi Liang
Anyi Liang
WQWeiwei Qin
Weiwei Qin
MZMeifen Zhang
Meifen Zhang
FGFei Gao
Fei Gao
CZChan Zhao
Chan Zhao
YGYouhe Gao
Youhe Gao
Purpose: To explore whether unilateral relapse of Bechet’s disease-associated uveitis (BDU) causes differences in the tear proteome between the diseased and the contralateral quiescent eye and potential tear biomarkers for uveitis recurrence and disease monitoring. Method: To minimize interindividual variations, bilateral tear samples were collected from the same patient (n = 15) with unilateral relapse of BDU. A data-independent acquisition (DIA) strategy was used to identify proteins that differed between active and quiescent eyes. Results: A total of 1,797 confident proteins were identified in the tear samples, of which 381 (21.2%) were also highly expressed in various tissues and organs. Fifty-one (2.8%) proteins differed in terms of expression between tears in active and quiescent eyes, 9 (17.6%) of which were functionally related to immunity or inflammation. Alpha-1-acid glycoprotein 1 (fold change = 3.2, p = 0.007) was increased and Annexin A1 (fold change = −1.7, p < 0.001) was decreased in the tears of the active BDU eye compared to the contralateral quiescent eye. Conclusions: A substantial amount of confident proteins were detected in the tears of BDU patients, including proteins that were deferentially expressed in the uveitis-relapsed eyes and the contralateral quiescent eyes. Some of these identified tear proteins play important roles in immune and inflammatory processes. Tear proteome might be a good source of biomarkers for uveitis.

9 July 2024 in BMC Ophthalmology
Verified
Journal Article
Open access
PDF file
WQWeiwei Qin
Weiwei Qin
ALAnyi Liang
Anyi Liang
XHXiaoxu Han
Xiaoxu Han
MZMeifen Zhang
Meifen Zhang
YGYouhe Gao
Youhe Gao
CZChan Zhao
Chan Zhao
Purpose: Behçet’s disease-associated uveitis (BDU) is a severe, recurrent inflammatory condition affecting the eye and is part of a systemic vasculitis with unknown etiology, making biomarker discovery essential for disease management. In this study, we intend to investigate potential urinary biomarkers to monitor the disease activity of BDU. Methods: Firstly, label-free data-dependent acquisition (DDA) and tandem mass tag (TMT)-labeled quantitative proteomics methods were used to profile the proteomes of urine from active and quiescent BDU patients, respectively. For further exploration, the remaining fifty urine samples were analyzed by a data-independent acquisition (DIA) quantitative proteomics method. Results: Twenty-nine and 21 differential proteins were identified in the same urine from BDU patients by label-free DDA and TMT-labeled analyses, respectively. Seventy-nine differentially expressed proteins (DEPs) were significantly changed in other active BDU urine samples compared to those in quiescent BDU urine samples by IDA analysis. Gene Ontology (GO) and protein-protein interaction (PPI) analyses revealed that the DEPs were associated with multiple functions, including the immune and neutrophil activation responses. Finally, seven proteins were identified as candidate biomarkers for BDU monitoring and recurrence prediction, namely, CD38, KCRB, DPP4, FUCA2, MTPN, S100A8 and S100A9. Conclusions: Our results showed that urine can be a good source of biomarkers for BDU. These dysregulated proteins provide potential urinary biomarkers for BDU activity monitoring and provide valuable clues for the analysis of the pathogenic mechanisms of BDU.

8 September 2025 in International Journal of Surgery
Verified
Journal Article
Open access
KJKehan Jin
Kehan Jin
LMLihui Meng
Lihui Meng
JYJingyuan Yang
Jingyuan Yang
CZChan Zhao
Chan Zhao
YCYouxin Chen
Youxin Chen
Objectives: To provide a bibliometric overview of the global research on the therapeutic applications of the suprachoroidal space (SCS) from 2000 to 2024. Methods: Publications were retrieved from the Web of Science Core Collection using a defined search strategy. A total of 776 articles were analyzed for trends in publication volume, countries, institutions, authorship, journals, citations, and keywords. An analysis of top 10% highly cited publications was also conducted. Co-authorship, co-occurrence, and citation burst analyses were conducted using VOSviewer, bibliometrix (R), and CiteSpace. Results: Global publications on SCS therapy increased steadily, with a 575% growth. The United States led in output (n = 274, 35.3%) and international collaboration. Top institutions included the University of Melbourne, Bionics Institute, and Osaka University. Fujikado Takashi was the most prolific author (34 publications), while Prausnitz Mark R R had the highest citation impact (50 per article). Investigative Ophthalmology & Visual Science was the most active journal (n = 50; 2249 citations). Keyword analysis revealed three main clusters: (1) drug delivery, (2) glaucoma treatment, and (3) retinal prosthesis. Overlay map indicated that research foci have shift from implantation to injection, minimally invasive approach, and clinical trials. Burst keywords showed suprachoroidal drug delivery (including gene therapy, ranibizumab, and triamcinolone acetonide) was a rapidly evolving and promising field for innovation, which was confirmed by analysis of high-impact publications. Conclusions: This study maps the global research landscape and emerging trends on the therapeutic applications of the SCS, underscores its translational nature, and fosters interdisciplinary collaboration in this evolving field.

17 August 2022 in International Journal of Ophthalmology
Verified
Journal Article
Closed access
JXJun-Yan Xiao
Jun-Yan Xiao
FGFei Gao
Fei Gao
CZChan Zhao
Chan Zhao
MZMeifen Zhang
Meifen Zhang
ALAn-Yi Liang
An-Yi Liang
AIM: To evaluate the effectiveness and corticosteroid-sparing capabilities of methotrexate (MTX) in the treatment of chronic non-necrotizing anterior scleritis in Chinese patients. METHODS: A retrospective chart review of all patients with active anterior scleritis between January 2015 and June 2019 was conducted. All patients received 10 to 15 mg/wk MTX orally, and corticosteroids (10 to 40 mg/d prednisolone or equivalent methylprednisolone) with slow tapering. Topical corticosteroid eye drops (1% prednisolone actate, 0.1% dexmathosone or 0.1% fluoromethalone) were applied to control comorbid anterior uveitis at presentation or during follow up. The main outcomes were inflammation control and corticosteroid-sparing success, and secondary outcomes were reduction of immunosuppression load and best-corrected visual acuity (BCVA). RESULTS: Thirty-two eyes (22 patients) were included. The proportion of patients who achieved corticosteroid-sparing success was 50.0% at 3mo and 77.3% at 12mo [8 (36.4%) patients discontinued corticosteroid]. The proportion of eyes that achieved inflammation control was 59.4% at 3mo and 78.1% at 12mo. The immunosuppression load was 5.14 +/- 0.87 at presentation and 2.76 +/- 2.34 at 12mo (P<0.01). BCVA maintained unchanged or improved in 29 (90.6%) of all affected eyes. One patient discontinued MTX treatment because of an abnormal liver function test, and no other serious adverse effects were observed. CONCLUSION: According to this pilot study, low dose MTX appear to be a well-tolerated and effective treatment for chronic non-necrotizing anterior scleritis patients in the Chinese population.